469 related articles for article (PubMed ID: 24497537)
41. Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.
Hughes S; Gumas J; Lee R; Rumano M; Berger N; Gautam AK; Sfyroera G; Chan AL; Gnanaguru G; Connor KM; Kim BJ; Dunaief JL; Ricklin D; Hajishengallis G; Yancopoulou D; Reis ES; Mastellos DC; Lambris JD
Clin Immunol; 2020 May; 214():108391. PubMed ID: 32229292
[TBL] [Abstract][Full Text] [Related]
42. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
Parker CJ; Wiedmer T; Sims PJ; Rosse WF
J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
[TBL] [Abstract][Full Text] [Related]
43. Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria.
Lin Z; Schmidt CQ; Koutsogiannaki S; Ricci P; Risitano AM; Lambris JD; Ricklin D
Blood; 2015 Aug; 126(7):891-4. PubMed ID: 26082452
[TBL] [Abstract][Full Text] [Related]
44. Upregulation of Checkpoint Ligand Programmed Death-Ligand 1 in Patients with Paroxysmal Nocturnal Hemoglobinuria Explained by Proximal Complement Activation.
Anliker M; Drees D; Loacker L; Hafner S; Griesmacher A; Hoermann G; Fux V; Schennach H; Hörtnagl P; Dopler A; Schmidt S; Bellmann-Weiler R; Weiss G; Marx-Hofmann A; Körper S; Höchsmann B; Schrezenmeier H; Schmidt CQ
J Immunol; 2022 Mar; 208(5):1248-1258. PubMed ID: 35173033
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Wong RSM; Pullon HWH; Amine I; Bogdanovic A; Deschatelets P; Francois CG; Ignatova K; Issaragrisil S; Niparuck P; Numbenjapon T; Roman E; Sathar J; Xu R; Al-Adhami M; Tan L; Tse E; Grossi FV
Ann Hematol; 2022 Sep; 101(9):1971-1986. PubMed ID: 35869170
[TBL] [Abstract][Full Text] [Related]
46. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
[TBL] [Abstract][Full Text] [Related]
47. The membrane abnormalities in paroxysmal nocturnal hemoglobinuria (PNH).
Rosse WF; Adams JP
Prog Clin Biol Res; 1979; 30():457-61. PubMed ID: 531036
[TBL] [Abstract][Full Text] [Related]
48. Safety profile after prolonged C3 inhibition.
Reis ES; Berger N; Wang X; Koutsogiannaki S; Doot RK; Gumas JT; Foukas PG; Resuello RRG; Tuplano JV; Kukis D; Tarantal AF; Young AJ; Kajikawa T; Soulika AM; Mastellos DC; Yancopoulou D; Biglarnia AR; Huber-Lang M; Hajishengallis G; Nilsson B; Lambris JD
Clin Immunol; 2018 Dec; 197():96-106. PubMed ID: 30217791
[TBL] [Abstract][Full Text] [Related]
49. Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.
Bodó I; Amine I; Boban A; Bumbea H; Kulagin A; Lukina E; Piekarska A; Zupan IP; Sokol J; Windyga J; Cermak J
Adv Ther; 2023 Jun; 40(6):2752-2772. PubMed ID: 37072660
[TBL] [Abstract][Full Text] [Related]
50. Effect of heparin on complement activation and lysis of paroxysmal nocturnal hemoglobinuria (PNH) red cells.
Logue GL
Blood; 1977 Aug; 50(2):239-47. PubMed ID: 17439
[TBL] [Abstract][Full Text] [Related]
51. The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments.
Lee JW; Brodsky RA; Nishimura JI; Kulasekararaj AG
Expert Rev Clin Pharmacol; 2022 Jul; 15(7):851-861. PubMed ID: 35980222
[TBL] [Abstract][Full Text] [Related]
52. [Novel therapeutics for paroxysmal nocturnal hemoglobinuria].
Nishimura JI
Rinsho Ketsueki; 2021; 62(5):463-471. PubMed ID: 34108330
[TBL] [Abstract][Full Text] [Related]
53. New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.
Berger N; Alayi TD; Resuello RRG; Tuplano JV; Reis ES; Lambris JD
J Med Chem; 2018 Jul; 61(14):6153-6162. PubMed ID: 29920096
[TBL] [Abstract][Full Text] [Related]
54. Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells.
Baas I; Delvasto-Nuñez L; Ligthart P; Brouwer C; Folman C; Reis ES; Ricklin D; Lambris JD; Wouters D; de Haas M; Jongerius I; Zeerleder SS
Haematologica; 2020; 105(2):e57-e60. PubMed ID: 31171642
[No Abstract] [Full Text] [Related]
55. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
[TBL] [Abstract][Full Text] [Related]
56. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
Front Immunol; 2019; 10():1639. PubMed ID: 31379839
[No Abstract] [Full Text] [Related]
57. Paroxysmal nocturnal hemoglobinuria.
Čermák J
Vnitr Lek; 2018; 64(5):508-513. PubMed ID: 30193519
[TBL] [Abstract][Full Text] [Related]
58. In vivo effects of various therapies on complement-sensitive erythrocytes in paroxysmal nocturnal hemoglobinuria.
Shichishima T; Saitoh Y; Noji H; Terasawa T; Maruyama Y
Int J Hematol; 1996 Jun; 63(4):291-302. PubMed ID: 8762812
[TBL] [Abstract][Full Text] [Related]
59. Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH.
Griffin M; Kelly RJ; Panse J; de Castro C; Szer J; Horneff R; Tan L; Yeh M; Peffault de Latour R
Blood Adv; 2024 Apr; 8(7):1776-1786. PubMed ID: 38315872
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters.
Reis ES; DeAngelis RA; Chen H; Resuello RR; Ricklin D; Lambris JD
Immunobiology; 2015 Apr; 220(4):476-82. PubMed ID: 25468722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
